BioNexus Gene Lab (BGLC) Liabilities and Shareholders Equity (2018 - 2026)

BioNexus Gene Lab has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $9.0 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 4.64% year-over-year to $9.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.3 million (down 15.97% YoY) and the FY2025 annual result came in at $9.3 million, down 11.32% from the prior year.
• Liabilities and Shareholders Equity eased to $9.0 million in Q1 2026 per BGLC's latest filing, from $9.3 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $11.5 million in Q3 2023 and troughed at $7.6 million in Q3 2025.
• A 5-year average of $9.5 million and a median of $9.3 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity soared 47.03% in 2023, then plunged 30.68% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $8.7 million in 2022, then soared by 30.43% to $11.4 million in 2023, then fell by 8.47% to $10.4 million in 2024, then fell by 11.32% to $9.3 million in 2025, then fell by 2.3% to $9.0 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $9.0 million, $9.3 million, and $7.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.